Retrophin Inc (NASDAQ:RTRX) – Investment analysts at William Blair dropped their Q2 2019 EPS estimates for Retrophin in a report released on Wednesday, May 8th, according to Zacks Investment Research. William Blair analyst T. Lugo now expects that the biopharmaceutical company will earn ($0.69) per share for the quarter, down from their prior estimate of ($0.66). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Retrophin’s Q4 2019 earnings at ($0.57) EPS, FY2019 earnings at ($2.87) EPS and FY2020 earnings at ($2.44) EPS.
Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.41). The company had revenue of $39.57 million during the quarter, compared to analysts’ expectations of $41.40 million. Retrophin had a negative return on equity of 41.38% and a negative net margin of 75.75%. Retrophin’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.14) EPS.
Several other research analysts have also recently weighed in on the stock. TheStreet cut shares of Retrophin from a “c-” rating to a “d+” rating in a research report on Friday, February 22nd. Svb Leerink reissued an “outperform” rating on shares of Retrophin in a research report on Tuesday, February 26th. Barclays initiated coverage on shares of Retrophin in a research report on Monday, April 22nd. They set an “overweight” rating and a $36.00 price target on the stock. BidaskClub cut shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. Finally, Zacks Investment Research raised shares of Retrophin from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 27th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $45.67.
Shares of RTRX stock traded up $0.17 on Monday, hitting $18.67. 397,973 shares of the stock traded hands, compared to its average volume of 373,875. The company has a current ratio of 4.57, a quick ratio of 4.52 and a debt-to-equity ratio of 0.69. The stock has a market cap of $767.82 million, a price-to-earnings ratio of -7.35 and a beta of 0.88. Retrophin has a twelve month low of $17.53 and a twelve month high of $33.00.
In other Retrophin news, CFO Laura Clague sold 2,500 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $18.25, for a total transaction of $45,625.00. Following the sale, the chief financial officer now directly owns 14,750 shares in the company, valued at $269,187.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Neil F. Mcfarlane sold 1,968 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $18.25, for a total transaction of $35,916.00. Following the sale, the chief operating officer now owns 27,972 shares in the company, valued at $510,489. The disclosure for this sale can be found here. Insiders sold 10,819 shares of company stock worth $194,503 in the last ninety days. 4.32% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the business. Advisor Group Inc. increased its stake in Retrophin by 1,824.0% during the first quarter. Advisor Group Inc. now owns 1,443 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,368 shares during the period. NumerixS Investment Technologies Inc purchased a new stake in Retrophin during the first quarter worth about $78,000. SG Americas Securities LLC purchased a new stake in Retrophin during the first quarter worth about $143,000. Campbell & CO Investment Adviser LLC purchased a new stake in Retrophin during the first quarter worth about $217,000. Finally, Legal & General Group Plc increased its stake in Retrophin by 33.5% during the third quarter. Legal & General Group Plc now owns 13,541 shares of the biopharmaceutical company’s stock worth $389,000 after purchasing an additional 3,395 shares during the period.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.